Raymond James Financial
CAPR icon

Raymond James Financial’s Capricor Therapeutics CAPR Stock Holding History

Raymond James Financial’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.97M Buy
196,300
+910
+0.5% +$24.2K ﹤0.01% 2454
2025
Q4 		$5.64M Buy
195,390
+4,098
+2% +$53.5K ﹤0.01% 2424
2025
Q3 		$1.38M Buy
191,292
+180,234
+1,630% +$1.33M ﹤0.01% 3461
2025
Q2 		$110K Sell
11,058
-58
-0.5% -$613 ﹤0.01% 4830
2025
Q1 		$105K Buy
+11,116
New +$154K ﹤0.01% 4539

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Raymond James Financial's CAPR Position: Q1 2026 in Review

Raymond James Financial increased its Capricor Therapeutics (CAPR) stake by 0.47% in Q1 2026, buying an estimated $24.2K and bringing the position to 196,300 shares worth $5.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

Raymond James Financial first reported a position in CAPR in Q1 2025 and has held it in 5 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Raymond James Financial held 196,300 shares of Capricor Therapeutics worth $5.97M as of Q1 2026.
  • Raymond James Financial bought 910 Capricor Therapeutics shares in Q1 2026, an estimated $24.2K.
  • Capricor Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2454 holding.
  • Raymond James Financial first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.